Cargando…

Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice

In fit metastatic colorectal cancer (MCRC), multidisciplinary treatment strategy integrating intensive FIr-B/FOx triplet chemotherapy associated to bevacizumab and secondary metastasectomies significantly improved clinical outcomes up to progression-free survival (PFS) 17 months and overall survival...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bruera, Gemma, Pepe, Francesco, Malapelle, Umberto, Di Staso, Mario, Dal Mas, Antonella, Di Giacomo, Daniela, Scerbo, Gaia, Santilli, Michela, Ciacco, Eugenio, Simmaco, Maurizio, Troncone, Giancarlo, Coco, Claudio, Giuliante, Felice, Ricevuto, Enrico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267302/ https://www.ncbi.nlm.nih.gov/pubmed/34277827 http://dx.doi.org/10.21037/atm-20-6636

Ejemplares similares

Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers
por: Bruera, Gemma, et al.
Publicado: (2019)

KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy
por: Bruera, Gemma, et al.
Publicado: (2018)

Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer
por: Bruera, Gemma, et al.
Publicado: (2018)

Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy
por: Bruera, Gemma, et al.
Publicado: (2020)

Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease
por: Bruera, Gemma, et al.
Publicado: (2012)

Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study
por: Bruera, Gemma, et al.
Publicado: (2018)

Biomarkers predictive value in early stage non-small cell lung cancer
por: Malapelle, Umberto, et al.
Publicado: (2020)

Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments
por: Bruera, Gemma, et al.
Publicado: (2020)

Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disease
por: Bruera, Gemma, et al.
Publicado: (2020)

Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer
por: Bruera, Gemma, et al.
Publicado: (2018)

Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice
por: Bruera, Gemma, et al.
Publicado: (2014)

Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice
por: Bruera, Gemma, et al.
Publicado: (2019)

A narrative review of lung cancer cytology in the times of coronavirus: what physicians should know
por: Pisapia, Pasquale, et al.
Publicado: (2020)

BRAF: A Two-Faced Janus
por: Pisapia, Pasquale, et al.
Publicado: (2020)

Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial
por: Rocco, Danilo, et al.
Publicado: (2019)

Liquid Biopsy in Prostate Cancer Management—Current Challenges and Future Perspectives
por: Crocetto, Felice, et al.
Publicado: (2022)

Cytology in the time of coronavirus disease (COVID-19): an Italian perspective
por: Vigliar, Elena, et al.
Publicado: (2021)

The Treatment of Advanced Melanoma: Therapeutic Update
por: Villani, Alessia, et al.
Publicado: (2022)

Nanoscale Prognosis of Colorectal Cancer Metastasis from AFM Image Processing of Histological Sections
por: Gavriil, Vassilios, et al.
Publicado: (2023)

Clinical parameters to guide decision-making in elderly metastatic colorectal cancer patients treated with intensive cytotoxic and anti-angiogenic therapy
por: Bruera, Gemma, et al.
Publicado: (2016)

EGFR exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: a case report and literature review
por: Pisapia, Pasquale, et al.
Publicado: (2019)

Universal Markers Unveil Metastatic Cancerous Cross-Sections at Nanoscale
por: Bakalis, Evangelos, et al.
Publicado: (2022)

Cytological and molecular diagnosis of solid variant of papillary thyroid carcinoma: A case report
por: Troncone, Giancarlo, et al.
Publicado: (2008)

Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study
por: Guadagni, Stefano, et al.
Publicado: (2019)

Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A
por: Guadagni, Stefano, et al.
Publicado: (2020)

Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study
por: Guadagni, Stefano, et al.
Publicado: (2019)

Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy)
por: de Biase, Dario, et al.
Publicado: (2013)

Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen
por: BRUERA, GEMMA, et al.
Publicado: (2014)

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype
por: BRUERA, GEMMA, et al.
Publicado: (2013)

Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
por: Bruera, Gemma, et al.
Publicado: (2013)

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

Next generation sequencing in cytology
por: Pisapia, Pasquale, et al.
Publicado: (2021)

Correction: Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Corte, Carminia Maria Della, et al.
Publicado: (2022)

KRAS detection on archival cytological smears by the novel fully automated polymerase chain reaction-based Idylla mutation test
por: De Luca, Caterina, et al.
Publicado: (2017)

Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study
por: Guadagni, Stefano, et al.
Publicado: (2020)

Analysis of Differential miRNA Expression in Primary Tumor and Stroma of Colorectal Cancer Patients
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report
por: Pepe, Francesco, et al.
Publicado: (2021)

Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases
por: Malapelle, Umberto, et al.
Publicado: (2016)

Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)
por: Bruera, Gemma, et al.
Publicado: (2013)

Next Generation Sequencing in Cytopathology: Focus on Non-Small Cell Lung Cancer
por: Pisapia, Pasquale, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s9gfrjs7l3vo3jqfn3ujapalr2